Philip Morris USA To Seek Further Review In The Douglas Case

Philip Morris USA said it plans to seek further review following today’s decision by the Florida Supreme Court in the Douglas case. The court’s opinion held that the current Engle progeny trial structure does not violate Florida Law and federal due process.

“We are reviewing the court’s decision and considering all of our options,” said Murray Garnick, senior vice president and associate general counsel, Altria Client Services, speaking on behalf of Philip Morris USA. “We believe that the court ruled incorrectly in allowing individual plaintiffs to use the general findings from the prior Engle case to prove their strict liability and negligence claims without showing that any wrongful conduct actually caused their injuries.”

In the dissent, Justice Canady said that the findings were “too slender [a] reed to support the imposition of liability.” Justice Canady stated that the majority’s analysis was “exactly backward” and that its reading of the findings was “unreasonable” and “unconvincing” because the findings do not establish “that all of the cigarettes sold by defendants were defective.”

The so-called Engle progeny cases stem from a 2006 Florida Supreme Court decision that decertified a class action but allowed former class members to file individual lawsuits and rely on general findings from the first class action.

The case is Douglas v. Philip Morris USA et al.

Copyright Business Wire 2010

If you liked this article you might like

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

CDC Director Steps Down Following Report She Invested in Big Tobacco Stocks

CDC Director Steps Down Following Report She Invested in Big Tobacco Stocks

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Hot Biotech ETF Finally Flashes Buy Signal

Hot Biotech ETF Finally Flashes Buy Signal